Engineered Liver-On-A-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Hepatology and drug development for liver diseases require in vitro liver models. Typical models include 2D planar primary hepatocytes, hepatocyte spheroids, hepatocyte organoids, and liver-on-a-chip. Liver-on-a-chip has emerged as the mainstream model for drug development because it recapitulates the liver microenvironment and has good assay robustness such as reproducibility. Liver-on-a-chip with human primary cells can potentially correlate clinical testing. Liver-on-a-chip can not only predict drug hepatotoxicity and drug metabolism, but also connect other artificial organs on the chip for a human-on-a-chip, which can reflect the overall effect of a drug. Engineering an effective liver-on-a-chip device requires knowledge of multiple disciplines including chemistry, fluidic mechanics, cell biology, electrics, and optics. This review first introduces the physiological microenvironments in the liver, especially the cell composition and its specialized roles, and then summarizes the strategies to build a liver-on-a-chip via microfluidic technologies and its biomedical applications. In addition, the latest advancements of liver-on-a-chip technologies are discussed, which serve as a basis for further liver-on-a-chip research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Organogenesis in a dish: Modeling development and disease using organoid technologies
Lancaster, M. A., & Knoblich, J. A. (2014) · Science · doi:10.1126/science.1247125 · Cited by 2,931 · cited 1×
“Currently, the liver models used for in vitro studies commonly include bioreactors (perfusion model of an isolated liver system) [7], 2D planar primary rat hepatocytes [8,9], 3D-printed liver tissue [10,11], liver organoids [12,13], and liver-on-a-chip systems [14–16].”
MethodConcordance of the toxicity of pharmaceuticals in humans and in animals
Olson, H., Betton, G., Robinson, D., Thomas, K., Monro, A., Kolaja, G., Lilly, P., Sanders, J., Sipes, G., Bracken, W., et al. (2000) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.2000.1399 · Cited by 2,050 · cited 1×
“For example, roughly half of the drugs found to be responsible for liver injury during clinical trials did not result in any damage in animal models in vivo [6].”
BackgroundHuman primary liver cancer–derived organoid cultures for disease modeling and drug screening
Broutier, L., Mastrogiovanni, G., Verstegen, M. M., Francies, H. E., Gavarró, L. M., Bradshaw, C. R., Allen, G. E., Arnes-Benito, R., Sidorova, O., Gaspersz, M. P., et al. (2017) · Nature Medicine · doi:10.1038/nm.4438 · Cited by 1,471 · cited 1×
“Currently, the liver models used for in vitro studies commonly include bioreactors (perfusion model of an isolated liver system) [7], 2D planar primary rat hepatocytes [8,9], 3D-printed liver tissue [10,11], liver organoids [12,13], and liver-on-a-chip systems [14–16].”
MethodGodoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · cited 2×
“In addition to the above five kinds of cells, there are many other kinds of cells in the liver, such as neutrophils, natural killer (NK) cells, and infiltrating macrophages [24].”
BackgroundMicroscale culture of human liver cells for drug development
Khetani, S. R., & Bhatia, S. N. (2008) · Nature Biotechnology · doi:10.1038/nbt1361 · Cited by 1,219
The immunology of hepatocellular carcinoma
Ringelhan, M., Pfister, D., O’Connor, T., Pikarsky, E., & Heikenwalder, M. (2018) · Nature Immunology · doi:10.1038/s41590-018-0044-z · Cited by 1,076 · cited 1×
“Recent studies have found that KCs also participate in antigen presentation [30].”
BackgroundLiver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Advances in organ-on-a-chip engineering
Zhang, B., Korolj, A., Lai, B. F. L., & Radisic, M. (2018) · Nature Reviews Materials · doi:10.1038/s41578-018-0034-7 · Cited by 1,017
Maschmeyer, I., Lorenz, A. K., Schimek, K., Hasenberg, T., Ramme, A. P., Hübner, J., Lindner, M., Drewell, C., Bauer, S., Thomas, A., et al. (2015) · Lab on a Chip · doi:10.1039/c5lc00392j · Cited by 861
A liver-on-a-chip platform with bioprinted hepatic spheroids
Bhise, N. S., Manoharan, V., Massa, S., Tamayol, A., Ghaderi, M., Miscuglio, M., Lang, Q., Shrike Zhang, Y., Shin, S. R., Calzone, G., et al. (2016) · Biofabrication · doi:10.1088/1758-5090/8/1/014101 · Cited by 615
Cited by
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
Self-citationFabrication and Applications of Microfluidic Devices: A Review
Niculescu, A.-G., Chircov, C., Bîrcă, A. C., & Grumezescu, A. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042011 · Cited by 678
Brown, M., Li, J., Moraes, C., Tabrizian, M., & Li-Jessen, N. Y. K. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121786 · Cited by 282
Lauschke, V. M., Shafagh, R. Z., Hendriks, D. F. G., & Ingelman‐Sundberg, M. (2019) · Biotechnology Journal · doi:10.1002/biot.201800347 · Cited by 153
Understanding the cellular interactome of non-alcoholic fatty liver disease
Wallace, S. J., Tacke, F., Schwabe, R. F., & Henderson, N. C. (2022) · JHEP Reports · doi:10.1016/j.jhepr.2022.100524 · Cited by 116
Olgasi, C., Cucci, A., & Follenzi, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176215 · Cited by 100
“However, the challenge remains to build up on the liver complexity; thus, new technologies, such as microfluidic and liver-on-chips, are rapidly developing [137] (Figure 3C).”
BackgroundImmune Organs and Immune Cells on a Chip: An Overview of Biomedical Applications
Morsink, M., Willemen, N., Leijten, J., Bansal, R., & Shin, S. (2020) · Micromachines · doi:10.3390/mi11090849 · Cited by 73
“It would be ideal to study drug metabolism on a liver-on-a-chip device, specifically one which models the liver metabolism on a chip [86,87].”
BackgroundLiver Tissue Engineering as an Emerging Alternative for Liver Disease Treatment
Mirdamadi, E. S., Kalhori, D., Zakeri, N., Azarpira, N., & Solati-Hashjin, M. (2020) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2019.0233 · Cited by 57
Bioinspired Artificial Liver System with hiPSC‐Derived Hepatocytes for Acute Liver Failure Treatment
Wang, J., Ren, H., Liu, Y., Sun, L., Zhang, Z., Zhao, Y., & Shi, X. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202101580 · Cited by 49
Sensors-integrated organ-on-a-chip for biomedical applications
Chen, H., Luo, Z., Lin, X., Zhu, Y., & Zhao, Y. (2023) · Nano Research · doi:10.1007/s12274-023-5651-9 · Cited by 47
Critical Considerations for the Design of Multi-Organ Microphysiological Systems (MPS)
Malik, M., Yang, Y., Fathi, P., Mahler, G. J., & Esch, M. B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.721338 · Cited by 43
Microfluidic Liver-on-a-Chip for Preclinical Drug Discovery
Fu, J., Qiu, H., & Tan, C. S. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041300 · Cited by 42
“Distinct types of cells form complicated transmission networks and metabolic environments through autocrine and paracrine signal transduction [29,30].”
BackgroundIn vitro functional models for human liver diseases and drug screening: beyond animal testing
Paradiso, A., Volpi, M., Rinoldi, C., Celikkin, N., Contessi Negrini, N., Bilgen, M., Dallera, G., Pierini, F., Costantini, M., Święszkowski, W., et al. (2023) · Biomaterials Science · doi:10.1039/d1bm01872h · Cited by 40
Ayuso, J. M., Sadangi, S., Lares, M., Rehman, S., Humayun, M., Denecke, K. M., Skala, M. C., Beebe, D. J., & Setaluri, V. (2021) · Lab on a Chip · doi:10.1039/d0lc00988a · Cited by 39
A Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44198-0 · Cited by 29
Microfluidic systems for modeling digestive cancer: a review of recent progress
Razavi, Z., Soltani, M., Pazoki-Toroudi, H., & Dabagh, M. (2024) · Biomedical Physics & Engineering Express · doi:10.1088/2057-1976/ad6f15 · Cited by 24
Bioartificial livers: a review of their design and manufacture
Tuerxun, K., He, J., Ibrahim, I., Yusupu, Z., Yasheng, A., Xu, Q., Tang, R., Aikebaier, A., Wu, Y., Tuerdi, M., et al. (2022) · Biofabrication · doi:10.1088/1758-5090/ac6e86 · Cited by 24
“Currently, microfluidic devices designed for hepatic research, namely the liver-on-a-chip, are widely applied in cell culturing, tissue or organ model construction, and drug testing [136–138].”
Metadata
- Authors
- Deng, J., Wei, W., Chen, Z., Lin, B., Zhao, W., Luo, Y., & Zhang, X.
- Venue
- Micromachines
- Publisher
- MDPI AG
- Published
- 2019-10-07
- Volume
- 10
- Issue
- 10
- Pages
- 676
- ISSN
- 2072-666X (ISSN-L)
- OpenAlex
- W2978924508
- Cited by
- 229
- References
- 30
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.